AVI Kurz vor dem Ziel / AVI BioPharma Announces FDA Clearance of IND - 500 Beiträge pro Seite
eröffnet am 24.12.08 15:59:54 von
neuester Beitrag 04.06.09 17:18:48 von
neuester Beitrag 04.06.09 17:18:48 von
Beiträge: 18
ID: 1.147.087
ID: 1.147.087
Aufrufe heute: 0
Gesamt: 4.726
Gesamt: 4.726
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| heute 00:10 | 321 | |
| heute 00:06 | 172 | |
| heute 01:16 | 143 | |
| heute 00:08 | 133 | |
| gestern 23:17 | 126 | |
| heute 03:03 | 110 | |
| 08.05.24, 11:56 | 110 | |
| gestern 21:23 | 110 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.659,00 | -0,43 | 87 | |||
| 2. | 2. | 10,330 | +0,19 | 69 | |||
| 3. | 3. | 9,5175 | -0,13 | 61 | |||
| 4. | 4. | 180,11 | -3,48 | 56 | |||
| 5. | 5. | 6,3590 | -0,61 | 52 | |||
| 6. | 6. | 15,700 | +5,30 | 48 | |||
| 7. | 7. | 102,30 | +11,11 | 48 | |||
| 8. | 8. | 2.370,77 | -0,33 | 38 |
Feedback
Press Release Source: AVI BioPharma, Inc.
Avi vor dem Durchbruch!
Und wir können hier am 24. nicht Reagieren.
Na dann mal Frohe Weihnachten!!!!!!
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Treatment of Ebola and Marburg Viruses
Tuesday December 23, 4:22 pm ET
PORTLAND, OR--(MARKET WIRE)--Dec 23, 2008 -- AVI BioPharma, Inc. (NasdaqGM:AVII - News), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) applications filed in November for its two lead products for Marburg and Ebola viruses. AVI BioPharma expects to receive written confirmation of the IND clearances from the FDA in early 2009.
ADVERTISEMENT
AVI-6002 and AVI-6003 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the morpholino oligomer linkage. Preclinical results of AVI-6002 and AVI-6003 demonstrated reproducible and high rates of survival in non-human primates challenged with a lethal infection of the Ebola and Marburg viruses.
Avi vor dem Durchbruch!
Und wir können hier am 24. nicht Reagieren.
Na dann mal Frohe Weihnachten!!!!!!
AVI BioPharma Announces FDA Clearance of IND Applications for Clinical Trials of RNA Therapeutic Agents for Treatment of Ebola and Marburg Viruses
Tuesday December 23, 4:22 pm ET
PORTLAND, OR--(MARKET WIRE)--Dec 23, 2008 -- AVI BioPharma, Inc. (NasdaqGM:AVII - News), a developer of RNA-based drugs, announced that it learned earlier today that it has received verbal clearance from the United States Food and Drug Administration (FDA) for the Investigational New Drug (IND) applications filed in November for its two lead products for Marburg and Ebola viruses. AVI BioPharma expects to receive written confirmation of the IND clearances from the FDA in early 2009.
ADVERTISEMENT
AVI-6002 and AVI-6003 are novel analogs based on AVI's PMO antisense chemistry in which anti-viral potency is enhanced by the addition of positively-charged components to the morpholino oligomer linkage. Preclinical results of AVI-6002 and AVI-6003 demonstrated reproducible and high rates of survival in non-human primates challenged with a lethal infection of the Ebola and Marburg viruses.
Kurs zieht an...
AVI BioPharma, Inc.
(NasdaqGM: AVII)
NEW Real-time: 0.8399 + 0.3499 (71.41%)
AVI BioPharma, Inc.
(NasdaqGM: AVII)
NEW Real-time: 0.8399 + 0.3499 (71.41%)
laber
Vor dem Ziel? 5-10 Jahre und hunderte Mio $ von dem Ziel.
Allerweltsmeldung.
New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.
Vor dem Ziel? 5-10 Jahre und hunderte Mio $ von dem Ziel.
Allerweltsmeldung.
New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.
Haben ein bisschen wenig Cash. Aber da es sich um RNA Antisense WS Pipeline handelt, stehen die Chancen mE sehr gut, dass die rel. schnell Partner bekommen. Und jetzt ist eigentlich die Zeit reif. Denn Biotechs mit Antisense Pipeline haben bezügl Partnerschaften iM sehr wenig Probleme. Und dann kommt uU die nötige Kohle rein.
Antwort auf Beitrag Nr.: 36.264.461 von -Salem- am 24.12.08 19:36:36tach zusammen...schaut euch mal telik an...
heute schon angelaufen..denke mal die news
kommen nach
heute schon angelaufen..denke mal die news
kommen nach
Trading Spotlight
Antwort auf Beitrag Nr.: 36.264.453 von -Salem- am 24.12.08 19:26:46Allerweltsmeldung.
New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.
Dafür das es eine Allerweltsmeldung gewesen sei soll ...lief es echt Prima!
Leider konnte ich nicht verkaufen ...das war wohl weniger toll... wird wohl so enden, so gewonnen so zerronnen.....
ich nehme es sportlich....
New Drug Applications verteilen die fast zu 99% an alle. Auch den 98% von den 99%, die dann später sterben. So wird es vermutlich auch hier sein.
Dafür das es eine Allerweltsmeldung gewesen sei soll ...lief es echt Prima!
Leider konnte ich nicht verkaufen ...das war wohl weniger toll... wird wohl so enden, so gewonnen so zerronnen.....
ich nehme es sportlich....
Läuft doch!!! Aushalten ist alles!!!! 
Potential bis 2 $ in den kommenden
Tagen.
Wichtig:
Nur als Zock ansehen.
Viele andere "flu virus shares" sind schon
heißgelaufen.
Tagen.
Wichtig:
Nur als Zock ansehen.
Viele andere "flu virus shares" sind schon
heißgelaufen.
Mon, Apr 27, 2009
07:08 AM
NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.
The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.
The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/ne… The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Health_News/2009/04/26/DHS-declares-swine… The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.
"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
07:08 AM
NanoViricides, Inc. Says Flu-Cide Drug Designed to Destroy All Influenza A Viruses Including Swine and Bird Flu
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced that it is developing FluCide(™), its flagship anti-influenza drug candidate, to work against all influenza types and subtypes. FluCide has been shown to be effective against both common influenza subtype H1N1, as well as two different variants of bird flu subtype H5N1.
The Company has previously announced excellent results in both animal studies and cell culture studies against widely different influenza subtypes and strains. If these results are confirmed in further animal and human studies, then FluCide would likely be considered the best ever drug effective against all influenzas. The Company is communicating its capabilities to various agencies involved in the current epidemic response.
The current swine flu outbreak is significant in that the H1N1 virus causing it is novel (http://www.cidrap.umn.edu/cidrap/content/influenza/panflu/ne… The US Department of Homeland Security has declared a Swine Flu Emergency yesterday. The WHO has said that the outbreak is an emergency of international concern (http://www.upi.com/Health_News/2009/04/26/DHS-declares-swine… The pig is known to be a transitional species for influenza viruses. That means re-assortment (i.e. mixing) of genes from bird flu, human flu, and swine flu viruses can take place in pigs. This can lead to more lethal, drug resistant novel strains to emerge from different existing ones.
"Nanoviricides(™) have clear advantages over antibodies and vaccines as antiviral strategies," said Dr. Diwan, President of NanoViricides. Antibodies are relatively specific to a particular virus strain or subtype. It is well known that HIV and influenza viruses among many others, quickly escape antibodies. Vaccines depend upon the development of antibodies by the host, and thus, cannot protect efficiently against those viruses which are continually changing their character, such as the influenza virus. Influenza vaccines in particular have to be developed with the strain that is expected to infect in the next year’s cycle. It is well known that this is not a failure-proof strategy for epidemic-causing strains that are novel.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for viral therapy. The Company's novel nanoviricide™ class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. The Company is developing drugs against a number of viral diseases including H5N1 bird flu, seasonal Influenza, HIV, EKC, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in pre-clinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com
Sorry, vorherige Meldung gehört zu
NNVC, mein weiterer Kandidat für
ordentliche Prozente.
Hat hier nichts zu suchen.
NNVC, mein weiterer Kandidat für
ordentliche Prozente.
Hat hier nichts zu suchen.
Antwort auf Beitrag Nr.: 37.047.847 von erdophus am 27.04.09 17:05:16Hab zu NNVC mal nen Thread aufgemacht, da ich keinen bestehenden gefunden habe:
http://www.wallstreet-online.de/diskussion/1149958-1-10/nano…
http://www.wallstreet-online.de/diskussion/1149958-1-10/nano…
Antwort auf Beitrag Nr.: 37.048.487 von tradepunk am 27.04.09 18:18:59Sehr schön...
servus...bin seit heute auch dabei.
leider etwas zu früh mit 0,92€ EK...werde aber morgen wohl nochmal nachlegen!!
seit wann seit ihr denn so dabei und was sind Eure Kurserwartungen für die nächsten Tage/Wochen mit AVI??
leider etwas zu früh mit 0,92€ EK...werde aber morgen wohl nochmal nachlegen!!
seit wann seit ihr denn so dabei und was sind Eure Kurserwartungen für die nächsten Tage/Wochen mit AVI??
Antwort auf Beitrag Nr.: 37.048.887 von Pokerlui007 am 27.04.09 19:12:34Hier bin ich bei 0,82€ rein. Hab noch 4 von den anderen Werten zu dem Thema: HXB, GB8, BO1 und NV3/NNVC.
Welcher am Besten läuft? - Keine Ahnung!
Wie hoch sie steigen? - Keine Ahnung!
Dürfte maßgeblich von der Stimmung und der Nachrichtenlage in den nächsten Tagen abhängen. Einfach mal dran und drin bleiben...
Welcher am Besten läuft? - Keine Ahnung!
Wie hoch sie steigen? - Keine Ahnung!
Dürfte maßgeblich von der Stimmung und der Nachrichtenlage in den nächsten Tagen abhängen. Einfach mal dran und drin bleiben...
Antwort auf Beitrag Nr.: 37.047.543 von erdophus am 27.04.09 16:36:41warum sollte dieser wert auf 2 euro hochgezockt werden? Kannst du das irgendwie belegen???
Ich kann da nix belegen.
Ist eine Einschätzung meinerseits.
Die letzten Zocks siehe H5N1 liefen
auch über mehrere Tage.
Ist eine Einschätzung meinerseits.
Die letzten Zocks siehe H5N1 liefen
auch über mehrere Tage.
Antwort auf Beitrag Nr.: 37.049.362 von erdophus am 27.04.09 20:12:39Wer noch drin ist, sollte dies auch bleiben...
Nächste Woche wird spannend....
Nächste Woche wird spannend....
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 87 | ||
| 69 | ||
| 61 | ||
| 56 | ||
| 52 | ||
| 48 | ||
| 48 | ||
| 38 | ||
| 35 | ||
| 29 |
| Wertpapier | Beiträge | |
|---|---|---|
| 26 | ||
| 26 | ||
| 25 | ||
| 25 | ||
| 23 | ||
| 23 | ||
| 23 | ||
| 22 | ||
| 21 | ||
| 20 |
